Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS

Go back to Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS
Entrx Corporation (NASDAQ: ENTX) Delayed: 3.05 --0 (-0%)
Previous Close $3.05    52 Week High $0.30 
Open $3.05    52 Week Low $0.10 
Day High $3.05    P/E N/A 
Day Low $3.05    EPS $0.00 
Volume 1,501